Viking TherapeuticsVKTX
VKTX
About: Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Employees: 36
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
80% more call options, than puts
Call options by funds: $296M | Put options by funds: $164M
15% more repeat investments, than reductions
Existing positions increased: 145 | Existing positions reduced: 126
6% less first-time investments, than exits
New positions opened: 81 | Existing positions closed: 86
1.09% less ownership
Funds ownership: 74.59% [Q3] → 73.51% (-1.09%) [Q4]
3% less funds holding
Funds holding: 418 [Q3] → 404 (-14) [Q4]
36% less capital invested
Capital invested by funds: $5.17B [Q3] → $3.3B (-$1.87B) [Q4]
75% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 2 (-6) [Q4]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
4%
upside
Avg. target
$83
188%
upside
High target
$125
333%
upside
11 analyst ratings
9 positive
82%
2 neutral
18%
0 negative
0%
Cantor Fitzgerald Steven Seedhouse 7% 1-year accuracy 1 / 14 met price target | 260%upside $104 | Overweight Initiated | 28 Apr 2025 |
Truist Securities Joon Lee 48% 1-year accuracy 20 / 42 met price target | 160%upside $75 | Buy Reiterated | 28 Apr 2025 |
Morgan Stanley Michael Ulz 30% 1-year accuracy 6 / 20 met price target | 253%upside $102 | Overweight Maintained | 24 Apr 2025 |
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 416 met price target | 253%upside $102 | Buy Reiterated | 24 Apr 2025 |
Goldman Sachs Richard Law 63% 1-year accuracy 5 / 8 met price target | 4%upside $30 | Neutral Initiated | 8 Apr 2025 |
Financial journalist opinion
Based on 27 articles about VKTX published over the past 30 days
Positive
The Motley Fool
15 hours ago
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual growth rate in the double digits from today over the next several years, with the market reaching $100 billion to $130 billion in the early 2030s.
Positive
The Motley Fool
1 day ago
Why Viking Therapeutics Stock Popped Again Today
Shares of Viking Therapeutics (VKTX 11.41%) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.
Positive
The Motley Fool
2 days ago
Why Viking Therapeutics Stock Popped Today
Viking Therapeutics (VKTX 0.40%) stock inched 2.3% higher through 10:20 a.m. ET Monday, and for a most curious reason.
Negative
MarketBeat
5 days ago
Viking Therapeutics Stock May Struggle After As-Expected Report
Viking Therapeutics Inc. NASDAQ: VKTX reported earnings after the market closed on Apr. 23. The stock is pushing higher as investors attempt to sort out a report that delivered no real news that investors hadn't heard.
Neutral
Seeking Alpha
6 days ago
Viking Therapeutics: Q1 Earnings Overview - Hard To Understand Wall Street's Pessimism
Viking Therapeutics' VK2735, a GLP-1 candidate, has driven significant share price gains but faces stiff competition from Eli Lilly and Novo Nordisk. Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future trials. VK2735's subcutaneous and oral formulations show promising weight loss results and safety, with Phase 3 and Phase 2 trials soon to be underway.
Negative
Zacks Investment Research
6 days ago
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips
VKTX's first-quarter earnings miss estimates. The company remains on track to start the late-stage development of its obesity injection before June-end.
Neutral
Seeking Alpha
6 days ago
Viking Therapeutics, Inc. (VKTX) Q1 2025 Earnings Call Transcript
Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q1 2025 Results Conference Call April 23, 2025 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Asim Rana - Truist Securities Mike Ulz - Morgan Stanley Ryan Deschner - Raymond James Jay Olson - Oppenheimer Hardik Parikh - JPMorgan Mayank Mamtani - B. Riley Securities Annabel Samimy - Stifel Roger Song - Jefferies Andy Hsieh - William Blair Biren Amin - Piper Sandler Thomas Smith - Leerink Partners George Farmer - Scotiabank Yale Jen - Laidlaw & Company Jeet Mukherjee - BTIG Operator Welcome to the Viking Therapeutics First Quarter 2025 Financial Results Conference Call.
Neutral
PRNewsWire
1 week ago
Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Phase 3 Trials for Subcutaneous VK2735 Expected to Begin 2Q25 Phase 2 VENTURE-Oral Dosing Trial in Obesity Fully Enrolled; Data Expected 2H25 Broad Manufacturing Agreement with CordenPharma to Support Future Commercialization of VK2735 Strong Quarter-End Cash Position of $852 Million SAN DIEGO , April 23, 2025 /PRNewswire/ --Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2025, and provided an update on its clinical pipeline and other corporate developments.
Positive
Zacks Investment Research
1 week ago
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Neutral
See It Market
1 week ago
Is Viking Therapeutics Stock (VKTX) Nearing A Bottom?
With earnings scheduled for the 23rd, Viking Therapeutic's (NASDAQ: VKTX) first-quarter investor call is expected to center around key pipeline updates. The spotlight will be on three clinical candidates: VK2735 (targeting obesity), VK2809 (for non-alcoholic steatohepatitis, or NASH), and VK0214 (for X-linked adrenoleukodystrophy, or X-ALD).
Charts implemented using Lightweight Charts™